Compare ATON & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATON | IMRN |
|---|---|---|
| Founded | 1973 | 1994 |
| Country | British Virgin Islands | Australia |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 12.0M |
| IPO Year | N/A | N/A |
| Metric | ATON | IMRN |
|---|---|---|
| Price | $1.46 | $1.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 1.2M |
| Earning Date | 11-28-2025 | 08-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,777,422.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 48.63 |
| 52 Week Low | $1.41 | $1.05 |
| 52 Week High | $15.82 | $2.48 |
| Indicator | ATON | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 28.95 |
| Support Level | N/A | $1.42 |
| Resistance Level | N/A | $1.78 |
| Average True Range (ATR) | 0.00 | 0.14 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 9.59 |
AlphaTON Capital Corp is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The company implements a comprehensive treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, it provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.